awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q38908779-A7D98B4A-34ED-4E8D-8526-BD4F5F349212
Q38908779-A7D98B4A-34ED-4E8D-8526-BD4F5F349212
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38908779-A7D98B4A-34ED-4E8D-8526-BD4F5F349212
The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes.
P2860
Q38908779-A7D98B4A-34ED-4E8D-8526-BD4F5F349212
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38908779-A7D98B4A-34ED-4E8D-8526-BD4F5F349212
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
f848bd31543e9a6666beead53e6343e75b51916f
P2860
Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients.